Mitral Valve Translocation Device for Functional Regurgitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for functional mitral regurgitation lack durability and effectiveness, with restrictive mitral annuloplasty showing high recurrence rates and prosthetic valve replacements carrying significant risks and complications.
Innovation Solution
A ring-shaped device with an annulus and leaflet portion is used to attach to the native mitral valve, allowing for translocation of the valve towards the apex of the heart, reducing leaflet tethering and increasing coaptation surface area, while preserving the original valve and chordae tendinae.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If restrictive mitral annuloplasty is performed, then mitral regurgitation is initially effective, but durability is poor with high recurrence rates
Solution Approach 1:
The patent applies valve translocation, moving the mitral valve from its original position to a new position within the left ventricle. This dimensional change in valve position addresses the root cause of functional mitral regurgitation by relocating the valve away from the dilated annulus, thereby achieving durable treatment without the high recurrence rates associated with restrictive annuloplasty alone.
2Reliability
If prosthetic valve replacement is performed, then durability is improved, but significant risks and complications arise
Solution Approach 1:
The patent extracts and removes the diseased mitral valve from its original position and relocates it to a different position within the left ventricle. This extraction and translocation approach preserves the patient's own valve tissue, avoiding the need for prosthetic replacement and its associated risks such as thromboembolism, infection, and degeneration, while still achieving durable treatment of functional mitral regurgitation.
3Ease of operation
If MitraClip procedure is used, then treatment is provided, but substantial number of patients have residual or recurrent mitral regurgitation
Solution Approach 1:
The patent employs valve translocation, moving the mitral valve to a new position within the left ventricle, which fundamentally changes the geometric relationships between the valve, annulus, and papillary muscles. This dimensional change in valve position provides more durable and effective treatment compared to the MitraClip procedure, which merely clips the leaflets together without addressing the underlying geometric distortion caused by ventricular dilation.
Data Source
AI summary
The present invention provides devices for treating functional mitral regurgitation and methods of use thereof. The devices translocate a subject's mitral valve in an apical direction. The devices thereby treat mitral regurgitation while preserving a subject's original mitral valve and chordae tendinae.